Fortress Biotech
FBIO
49 hedge funds and large institutions have $18M invested in Fortress Biotech in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 15 closing their positions.
0.17% less ownership
Funds ownership: 1.86% → 1.69% (-0.17%)
23% less funds holding
Funds holding: 64 → 49 (-15)
30% less capital invested
Capital invested by funds: $25.8M → $18M (-$7.82M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$3.17M |
| 2 |
TI
Telemetry Investments
New York
|
+$53.1K |
| 3 |
1WM
1900 Wealth Management
San Antonio,
Texas
|
+$22.1K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$22.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.61M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$700K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$218K |
| 4 |
Renaissance Technologies
New York
|
-$146K |
| 5 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$82.1K |
FBIO Hedge Fund Activity: Q4 2022 in Review
49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q4 2022, worth a combined $18M — down 30% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of FBIO and 5 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $3.17M. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.61M sold.
- 49 institutional investors held Fortress Biotech (FBIO) as of Q4 2022, down from 64 in Q3 2022.
- Funds reported $18M of Fortress Biotech stock for Q4 2022, down 30% quarter-over-quarter.
- 5 funds opened new Fortress Biotech positions in Q4 2022 and 15 closed out, a net change of -10 holders.
- The largest Fortress Biotech buyer in Q4 2022 was Jefferies Financial Group, an estimated $3.17M added.
- The largest Fortress Biotech seller in Q4 2022 was Tang Capital Management, an estimated $3.61M sold.
Based on aggregated 13F filings for Q4 2022.